Simultaneous detection of clinically relevant mutations and amplifications for routine cancer pathology.
暂无分享,去创建一个
Edwin Cuppen | Isaac J Nijman | Marlous Hoogstraat | Stefan M Willems | Ton Peeters | E. Cuppen | E. Voest | I. Nijman | M. Hoogstraat | M. Koudijs | S. Willems | N. Besselink | R. D. de Weger | Emile E Voest | J. Hinrichs | Joyce H Radersma-van Loon | Carmen M A de Voijs | T. Peeters | Roel A de Weger | John W J Hinrichs | Nicolle J M Besselink | Marco J Koudijs | Nicolle J. M. Besselink | Ton Peeters
[1] G R Taylor,et al. Diagnosis of copy number variation by Illumina next generation sequencing is comparable in performance to oligonucleotide array comparative genomic hybridisation. , 2013, Genomics.
[2] Rashmi Kanagal-Shamanna,et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.
[3] Seung-Yong Jeong,et al. Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing , 2013, PloS one.
[4] J. Lee,et al. P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy , 2013, Oncotarget.
[5] M. Odenthal,et al. Deep ion sequencing of amplicon adapter ligated libraries: a novel tool in molecular diagnostics of formalin fixed and paraffin embedded tissues , 2013, Journal of Clinical Pathology.
[6] Yu-ping Wang,et al. Comparative Studies of Copy Number Variation Detection Methods for Next-Generation Sequencing Technologies , 2013, PloS one.
[7] Ashish Choudhary,et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. , 2013, The Journal of molecular diagnostics : JMD.
[8] J. Leamon,et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. , 2013, The Journal of molecular diagnostics : JMD.
[9] A. Antón,et al. Advanced HER2-positive gastric cancer: current and future targeted therapies. , 2013, Critical reviews in oncology/hematology.
[10] B. Neyns,et al. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. , 2012, International journal of oncology.
[11] John D Pfeifer,et al. Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia , 2012, Modern Pathology.
[12] T. Hudson,et al. The Genetic Basis for Cancer Treatment Decisions , 2012, Cell.
[13] E. Wall,et al. Current technologies for HER2 testing in breast cancer. , 2011, Critical reviews in oncology/hematology.
[14] G. Tse,et al. Epidermal growth factor receptor gene amplification and protein overexpression in basal‐like carcinoma of the breast , 2011, Histopathology.
[15] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[16] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[17] R. Osamura,et al. Evaluation of HER2 gene amplification in invasive breast cancer using a dual‐color chromogenic in situ hybridization (dual CISH) , 2010, Pathology international.
[18] K. Maclennan,et al. Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens , 2010, Nucleic acids research.
[19] Paul Medvedev,et al. Computational methods for discovering structural variation with next-generation sequencing , 2009, Nature Methods.
[20] L. Campbell,et al. Gene amplification in myeloid leukemias elucidated by fluorescence in situ hybridization. , 2009, Cancer genetics and cytogenetics.
[21] A. Kaye,et al. The EGFRvIII variant in glioblastoma multiforme , 2009, Journal of Clinical Neuroscience.
[22] Paul J. van Diest,et al. HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization , 2008, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[23] A. Jimeno,et al. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] N. Hanna,et al. EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .
[25] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[26] J. Isola,et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[28] E. Cameron,et al. Amplification of the ABL gene in T-cell acute lymphoblastic leukemia , 2004, Leukemia.
[29] D. Zwijnenburg,et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.
[30] A. Hagemeijer,et al. MLL amplification in myeloid leukemias: A study of 14 cases with multiple copies of 11q23 , 2000, Genes, chromosomes & cancer.
[31] Teri A. Crosby,et al. How to Detect and Handle Outliers , 1993 .